Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 55.56

+1.3%

3:30 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: former_pgs who wrote (14727)	12/21/2004 12:55:48 PM
From: tuck	Read Replies (1) of 52153

Corante blogger and friends offer some insight into the Celebrex mystery. Why did the same dose give different results: because it's not really the same dose: corante.com Be sure to click the "comments" link for the whole story. It notes that Pfizer's second trial (which the company says conflicts with the NCI results, as they haven't seen any CV signals) started a year after the NCI studies that have produced the CV signals, and suggests that it, too, will produce them in another year or so. Despite Pfizer's current stance of not yanking Celebrex from the market, odds look pretty good that they'll be forced to eventually, or at least to have Celebrex' use restricted. One wonders if continued sales of Celebrex going forward will offset the higher legal exposure of keeping it on the market. I doubt it. Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next